Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 4 minute read Pharma Industry News Jacobio Pharma secures $2bn global licensing agreement with AstraZeneca for JAB-23E73 Jacobio Pharma’s $2B global licensing deal with AstraZeneca could reshape KRAS inhibitor strategy in oncology. Read the full breakdown of the partnership now. byPallavi MadhirajuDecember 22, 2025